Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 91

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 91
---
| Granted |     | IN      |     | Oct.        
 19, 2016    |     | Liposomal         
 Mupirocin         |     | 201627035738 |     | November 
 23, 2020 |     |          351893 |     | April   
 8, 2035 |

Market Opportunity and Estimated Commercial Potential for Systemic Liposomal Nano-Mupirocin

Clinical Background and Unmet Need

Gonorrhea, caused by Neisseria gonorrhoeae, is
one of the most common sexually transmitted infections globally. The U.S. Centers for Disease Control and Prevention (CDC) recommends
Ceftriaxone as the first-line treatment [2]. Resistance is a growing threat. However, strains resistant to Ceftriaxone are emerging,
posing a serious public health threat [3].

We are working to develop Liposomal Mupirocin
as a systemic treatment alternative for Ceftriaxone-resistant infections, with the potential to offer improved tissue penetration, higher
drug concentration at the site of the infection and sustained drug exposure.

<div align='center'>57</div>

Pricing Benchmark and Market Assumptions

Our pricing assumptions are based on comparison
between conventional small-molecule drugs and their nanoparticle/liposomal equivalents. For example, conventional Amphotericin B averages
approximately $51 per 50 mg dose (source: Drugs.com price guide), whereas liposomal Amphotericin B (AmBisome®) averages approximately
$341 per dose, reflecting a ~7x premium (Lee et al., Lancet Global Health, Sept 2024, “Paving the way for affordable and
equitable liposomal amphotericin B access worldwide”).

For Liposomal Nano-Mupirocin, we benchmarked against:

| - | Ceftriaxone: the current recommended                                                       
 treatment for uncomplicated gonorrhea (including resistant strains) as recommended by CDC. 
 Average price per treatment course is $538 [5]                                             |

| - | Topical Mupirocin (~$45 per 50g). [6] |

| - | Based on these benchmarks and the                                                               
 ~7x premium commonly observed for liposomal formulations, we estimate a potential treatment     
 course price of $315–$1,200, depending on market segment, with an illustrative base             
 case of $600. The lower end of this range corresponds to assumptions of low-income or